How I treat primary cutaneous CD301 lymphoproliferative disorders

12Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The primary cutaneous CD301 lymphoproliferative disorders are a family of extranodal lymphoid neoplasms that arise from mature postthymic T cells and localize to the skin. Current classification systems recognize lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma, and borderline cases. In the majority of patients, the prognosis of primary cutaneous CD301 lymphoproliferative disorders is excellent; however, relapses are common, and complete cures are rare. Skin-directed and systemic therapies are used as monotherapy or in combination to achieve the best disease control and minimize overall toxicity. We discuss 3 distinct presentations of primary cutaneous CD301 lymphoproliferative disorder and present recommendations for a multidisciplinary team approach to diagnosis, evaluation, and management of these conditions in keeping with existing consensus guidelines.

Cite

CITATION STYLE

APA

Shinohara, M. M., & Shustov, A. (2019). How I treat primary cutaneous CD301 lymphoproliferative disorders. Blood, 134(6), 515–524. https://doi.org/10.1182/blood.2019000785

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free